OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome

Tumor-induced Osteomalacia (TIO) is a rare condition in which excess FGF23 produced by a tumor leads to renal phosphate wasting, impaired 1,25(OH)(2)D synthesis, osteomalacia, fractures, weakness, fatigue, and decreased mobility. In an ongoing open-label Phase 2 study (NCT02304367), 17 adults with T...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpenter, Thomas O, Miller, Paul D, Weber, Thomas J, Peacock, Munro, Insogna, Karl L, Kumar, Rajiv, Luca, Diana, Cimms, Tricia, Roberts, Mary Scott, de Beur, Suzanne Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208350/
http://dx.doi.org/10.1210/jendso/bvaa046.403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208350/
http://dx.doi.org/10.1210/jendso/bvaa046.403

Ejemplares similares